Trial Profile

A Phase 1 double blind, randomized, placebo-controlled trial of HNSA-5487 in healthy male and female adult participants

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HNSA-5487 (Primary)
Indications Autoimmune disorders; Cancer
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
Acronyms NICE-01
Sponsors Hansa Biopharma AB

Most Recent Events

07 Oct 2024 According to a Hansa Biopharma AB media release,positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487 were presented.
07 Oct 2024 Results published in the Hansa Biopharma AB Media Release
26 Oct 2023 According to a Hansa Biopharma AB media release, Further analysis around endpoints to be completed in 2024 .

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com